Biotech News

MoonLake Immunotherapeutics Announces Pricing of Upsized $200 Million Public Offering

MoonLake Immunotherapeutics (MLTX)MoonLake Immunotherapeutics2026-06-25 13:46 ESTFinancing

ZUG, Switzerland, June 23, 2026 – MoonLake Immunotherapeutics (NASDAQ: MLTX) (“MoonLake”), a clinical-stage biotechnology company focused on creating next-level therapies for inflammatory skin and joint diseases, today announced the pricing of an underwritten public offering of 9,000,000 Class A

Open original release

Related news

MLTXMoonLake Immunotherapeutics2026-06-25 13:46 EST

MoonLake Immunotherapeutics Announces Proposed Public Offering

MLTXMoonLake Immunotherapeutics2026-06-25 13:46 EST

MoonLake Announces Week 52 Results of Sonelokimab from its Phase 3 VELA Program in Hidradenitis Suppurativa and Confirms Investor Day on June 22, 2026

MLTXMoonLake Immunotherapeutics2026-06-25 13:46 EST

MoonLake Immunotherapeutics Announces Positive Outcome from its Final Pre-BLA Meeting with the U.S. FDA and Reports First Quarter 2026 Financial Results

MLTXMoonLake Immunotherapeutics2026-06-25 13:46 EST

MoonLake Immunotherapeutics to host a Capital Markets Day on Tuesday, April 29

MLTXMoonLake Immunotherapeutics2026-06-25 13:46 EST

MoonLake Immunotherapeutics Reports First Quarter 2025 Financial Results and Provides a Business Update

MLTXMoonLake Immunotherapeutics2026-06-25 13:46 EST

MoonLake Immunotherapeutics Reports Second Quarter 2025 Financial Results and Provides a Business Update

MLTXMoonLake Immunotherapeutics2026-06-25 13:46 EST

MoonLake Immunotherapeutics reports on week 16 results of the VELA Phase 3 hidradenitis suppurativa program with the Nanobody® sonelokimab

MLTXMoonLake Immunotherapeutics2026-06-25 13:46 EST

MoonLake Immunotherapeutics Reports Third Quarter 2025 Financial Results and Announces New Data from Clinical Trials of its Nanobody® Sonelokimab

MLTXMoonLake Immunotherapeutics2026-06-25 13:46 EST

MoonLake Immunotherapeutics Announces Pricing of $75 Million Underwritten Offering

MLTXMoonLake Immunotherapeutics2026-06-25 13:46 EST

MoonLake Immunotherapeutics Announces Positive Outcome from Type B Meeting with U.S. FDA and Announces Investor Day

View all latest news

MoonLake Immunotherapeutics

MoonLake Immunotherapeutics is an immunology-oriented biopharmaceutical company focused on inflammatory and immune-mediated disease programs, where each new data point can reshape expectations for the pipeline and the next catalyst window.

Recent company news

MLTXMoonLake Immunotherapeutics2026-06-26 07:10 EST

MoonLake Immunotherapeutics Announces Pricing of Upsized $200 Million Public Offering

MLTXMoonLake Immunotherapeutics2026-06-26 07:10 EST

MoonLake Immunotherapeutics Announces Proposed Public Offering

MLTXMoonLake Immunotherapeutics2026-06-26 07:10 EST

MoonLake Announces Week 52 Results of Sonelokimab from its Phase 3 VELA Program in Hidradenitis Suppurativa and Confirms Investor Day on June 22, 2026

MLTXMoonLake Immunotherapeutics2026-06-26 07:10 EST

MoonLake Immunotherapeutics Announces Positive Outcome from its Final Pre-BLA Meeting with the U.S. FDA and Reports First Quarter 2026 Financial Results

MLTXMoonLake Immunotherapeutics2026-06-26 07:10 EST

MoonLake Immunotherapeutics to host a Capital Markets Day on Tuesday, April 29

Stock data

Close: —
Market cap: —
Exchange: NASDAQ
Sector: Biotechnology
Location: United States